RecruitingNCT05356039
Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer
Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer - a Multicenter Prospective Observational Study
Sponsor
Umeå University
Enrollment
300 participants
Start Date
Apr 19, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to assess overall survival, quality of life and resection rates in locally advanced pancreatic cancer
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is following and collecting data on people with locally advanced pancreatic cancer — tumors that have grown into nearby blood vessels or tissue but have not yet spread to distant organs — to understand which patients benefit most from surgery, chemotherapy, or other treatment combinations.
**You may be eligible if...**
- You have a confirmed or suspected invasive pancreatic cancer
- Your tumor is classified as borderline resectable or locally advanced (meaning it may or may not be operable) according to standard oncology guidelines
- You are 18 or older
**You may NOT be eligible if...**
- Your tumor is a pancreatic endocrine (hormone-producing) tumor rather than the common type
- You have cancer arising near the pancreas but not within the pancreas itself (non-pancreatic periampullary tumor)
- Your cancer has spread to distant organs (e.g., liver, lungs)
- You are unable to understand or consent to participation due to language, mental, or cognitive barriers
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05356039
Related Trials
Optimization of Transcranial Motor Evoked Potentials in Supratentorial Surgeries
NCT064803701 location
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
NCT071570334 locations
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
NCT060503171 location
Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).
NCT075618921 location
Shared Decision Making in Patients With Lung Cancer
NCT051914851 location